RYAM CEO's Exit Sparks Strategic Review: Translation, We're Officially Lost

Scott M. Sutton's resignation as President and CEO of Rayonier Advanced Materials, effective April 16, 2026, arrived with the kind of abruptness that markets have learned to interpret as a flashing red light. Within hours, the board announced a formal strategic review exploring, in the delicate language of governance theatre, 'a wide range of potential strategic, business and financial options.' Translation: everything is on the table, including a possible sale of all or part of the company.

This is corporate code at its finest. The sequence matters. CEO exits first. Strategic review materializes second. The interval between them is usually measured in conference calls, not quarters. It's the boardroom equivalent of your doctor saying 'we're going to run some tests' after you describe chest pain. You know something is wrong. The board definitely knows something is wrong. But nobody is saying it out loud yet.

For a company that generated $1.5 billion in revenue last year, this particular pivot suggests the business model has developed some uncomfortable questions that Sutton either couldn't answer or declined to address from the executive suite. The unsolicited indications of interest—the formal trigger for the review—hint that external parties already sense opportunity in RYAM's distress. Whether that's a compliment or a vulture assessment remains unclear.

The board's interim structure offers a useful window into the chaos underneath. Rather than anoint a single successor, they've created what they're calling an Office of the Chief Executive Officer staffed by four executives: Marcus J. Moeltner, the CFO, serving as interim principal executive officer; Michael Osborne, Vice President of Manufacturing Operations; Christian Ribeyrolle, Senior Vice President of Biomaterials; and R. Colby Slaughter, Senior Vice President, General Counsel and Corporate Secretary. This is how boards signal that nobody on the current roster is ready to lead the company going forward. It's a holding pattern dressed up as shared leadership.

Morgan Stanley and Wachtell, Lipton, Rosen & Katz are now running the show, which means months of data room access, management presentations, and endless permutations of who might buy what at what price. The board has explicitly refused to set a timetable, which is corporate-speak for 'this could take longer than anyone's comfortable acknowledging.' They've also buried the lede: 'There is no assurance the process will result in any transaction.' Translation again: we might spend nine months and six figures in advisory fees only to announce we're staying independent.

The market has already issued its own judgment. RYAM's stock fell 11.31 percent to $9.06, shedding $1.15 on the day of the announcement. That's not surprise. That's capitulation. Investors understand what a strategic review actually means: prolonged uncertainty, executive distraction, and the high probability that when this exercise concludes, the business will be either sold at a discount or reconstituted under new management with a new strategy that should have been executed twelve months ago.

Sutton's departure removes the person who was supposed to have answers. His replacement—or more accurately, his interim replacements—are managing the decline while Wall Street's finest figure out whether RYAM has a future or just a valuation. The board's caution about timelines and outcomes is not modesty. It's acknowledgment that they're genuinely uncertain about which direction this goes. For shareholders accustomed to clarity, that uncertainty is worth eleven percentage points.